A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First[95]-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone With or Without Bevacizumab as First[95]-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Ixabepilone (Primary) ; Paclitaxel (Primary) ; Bevacizumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms Alliance
  • Most Recent Events

    • 24 Mar 2018 Results of analysis trying to incorporate pharmacogenomic data from associations SNPs and the variability of model estimated parameters to improve model prediction of chemotherapy induced peripheral neuropathy presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 24 Mar 2018 Results of pharmacogenomic study identifying genetic variants that influence the susceptibility for developing MTA-induced SPN presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 09 Dec 2017 Results assessing predictive utility of serial CTC analysis, presented at the 40th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top